Funded Activity Summary
For women under 50 years with hormone receptor positive (ER+) breast cancer, adjuvant treatment with chemotherapy, tamoxifen and ovarian ablation are each effective and reduce recurrence. Combining two treatments is more effective than one, although it is uncertain if combining three provides extra benefit. Ovarian ablation by surgery or radiation is permanent, but reversible ovarian suppression by injections is now available. Three international trials called SOFT, TEXT and PERCHE have been designed for adjuvant therapy of premenopausal women with ER+ breast cancer. These trials take into account regional-country variations in medical practice and different patient choices in this setting. SOFT is for very young women and tests the benefit of adding ovarian suppression in a woman who has received chemotherapy, with tamoxifen planned, but who has not gone into menopause after chemotherapy. The trial also tests if substituting a newer drug called exemestane for tamoxifen, combined with ovarian function suppression is more effective. TEXT is for women who would ordinarily be treated with ovarian suppression plus tamoxifen. The TEXT trial also tests substitution of exemestane for tamoxifen. Exemestane is an aromatase inhibitor. Aromatase inhibitors lower oestrogen levels, but only work if the ovaries are inactive. Recent trials in post menopausal women show aromatase inhibitors are more effective than tamoxifen, and we aim to replicate that improvement in younger women by combining exemestane with ovarian suppression. PERCHE is for women in whom the benefit of chemotherapy is uncertain, for example those with limited or no spread to lymph nodes. All women receive combined endocrine treatment with ovarian suppression plus tamoxifen, and are randomised to receive in addition, either chemotherapy or no chemotherapy, to see if results differ.
Funded Activity Details
Start Date:
2005
End Date:
2007
Funding Scheme:
NHMRC Project Grants
Funding Amount:
$257,250.00
Funder: National Health and Medical Research Council
Research Topics
ANZSRC Field of Research (FoR)
Oncology and Carcinogenesis
ANZSRC Socio-Economic Objective (SEO)
There are no SEO codes available for this funding activity
Related Links
Related Researchers
No related researchers have been discovered for grant Tailored Treatments for Premenopausal Patients with Endocrine Responsive Breast Cancer..
Related Organisations
No related organisations have been discovered for grant Tailored Treatments for Premenopausal Patients with Endocrine Responsive Breast Cancer..